Hsu Hui-Chen, Yang Pingar, Wu Qi, Wang John H, Job Godwin, Guentert Tanja, Li Jun, Stockard Cecil R, Le Thuc-Vy L, Chaplin David D, Grizzle William E, Mountz John D
University of Alabama at Birmingham, Birmingham, AL, USA.
Arthritis Rheum. 2011 Jul;63(7):2038-48. doi: 10.1002/art.30257.
To determine whether functional suppression of the catalytic domain of activation-induced cytidine deaminase (AID) can suppress the hyperreactive germinal center (GC) responses in BXD2 mice.
We generated transgenic BXD2 mice expressing a dominant-negative (DN) form of Aicda at the somatic hypermutation site (BXD2-Aicda-DN-transgenic mice). Real-time quantitative reverse transcriptase-polymerase chain reaction was used to determine the expression of Aicda and DNA damage/repair genes. Enzyme-linked immunosorbent assay was used to measure serum levels of autoantibodies and immune complexes (ICs). Development of GCs and antibody-containing ICs as well as numbers of proliferative and apoptotic cells were determined using flow cytometry and/or immunohistochemical analyses. Development of arthritis and kidney disease was evaluated histologically in 6-8-month-old mice.
Suppression of the somatic hypermutation function of AID resulted in a significant decrease in autoantibody production without affecting the expression of DNA damage-related genes in GC B cells of BXD2-Aicda-DN-transgenic mice. There was decreased proliferation, increased apoptosis, increased expression of caspase 9 messenger RNA in GC B cells, and lower numbers of GCs in the spleens of BXD2-Aicda-DN-transgenic mice. Decreased GC response was associated with lower levels of IgG-containing ICs. Anti-IgM- and anti-CD40 plus anti-Ig-induced B cell proliferative responses were decreased in BXD2-Aicda-DN-transgenic mice.
Inhibition of the AID somatic hypermutation function in BXD2 mice suppressed development of spontaneous GCs, generation of autoantibody-producing B cells, and autoimmunity in BXD2 mice. Suppression of AID catalytic function to limit selection-based survival of GC B cells could become a novel therapy for the treatment of autoimmune disease.
确定激活诱导的胞苷脱氨酶(AID)催化结构域的功能抑制是否能抑制BXD2小鼠中高反应性生发中心(GC)反应。
我们构建了在体细胞超突变位点表达显性负性(DN)形式的Aicda的转基因BXD2小鼠(BXD2-Aicda-DN转基因小鼠)。采用实时定量逆转录聚合酶链反应来确定Aicda和DNA损伤/修复基因的表达。酶联免疫吸附测定法用于检测血清中自身抗体和免疫复合物(ICs)的水平。使用流式细胞术和/或免疫组织化学分析来确定GCs和含抗体ICs的发育情况以及增殖和凋亡细胞的数量。对6至8月龄小鼠的关节炎和肾脏疾病发展进行组织学评估。
AID体细胞超突变功能的抑制导致BXD2-Aicda-DN转基因小鼠GC B细胞中自身抗体产生显著减少,而不影响DNA损伤相关基因的表达。BXD2-Aicda-DN转基因小鼠的脾脏中,GC B细胞增殖减少、凋亡增加、半胱天冬酶9信使核糖核酸表达增加且GC数量减少。GC反应降低与含IgG的ICs水平降低有关。BXD2-Aicda-DN转基因小鼠中抗IgM以及抗CD40加抗Ig诱导的B细胞增殖反应降低。
抑制BXD2小鼠中AID的体细胞超突变功能可抑制BXD2小鼠中自发性GCs的发育、产生自身抗体的B细胞的生成以及自身免疫。抑制AID催化功能以限制基于选择的GC B细胞存活可能成为治疗自身免疫性疾病的新疗法。